{"podcast":{"title":"Hematologic Oncology Update","slug":"hematologic-oncology-update-916423","podcast_index_feed_id":916423,"rss_url":"https://feeds.captivate.fm/hematologic-oncology/","website_url":"https://www.researchtopractice.com/browse-tumor-types/hematologic-oncology","image_url":"https://artwork.captivate.fm/385e0bc2-3e77-4650-a103-033cd89470e0/VM1-kJu7V4rmiKPVI6DGtcq3.png","author":"Dr. Neil Love","episode_count":161,"summary":"Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.","last_synced_at":"2026-09-26T04:24:25.521627+00:00","page_url":"https://stenobird.com/podcast/hematologic-oncology-update-916423"},"episode":{"title":"Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov","slug":"antibody-drug-conjugates-for-multiple-myeloma-an-interview-with-dr-douglas-w-sborov","published_at":"2026-09-23T18:00:00+00:00","page_url":"https://stenobird.com/podcast/hematologic-oncology-update-916423/antibody-drug-conjugates-for-multiple-myeloma-an-interview-with-dr-douglas-w-sborov","show_page_url":"https://stenobird.com/podcast/hematologic-oncology-update-916423","url":"https://hematologic-oncology.captivate.fm/episode/6152-oncologytodayadcsmm26","audio_url":"https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/4e784545-c3b6-4dd0-b0a7-5abf63fc1a5f.mp3","summary":"Featuring an interview with Dr Douglas W Sborov, including the following topics: DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00) Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26) Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36) Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48) Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00) Prevention and management of ophthalmic events related to treatment with belamaf (21:27) Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49) Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27) Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53) CME information and select publications","meta_description":"Featuring an interview with Dr Douglas W Sborov, including the following topics: DREAMM-2 trial outcomes and clinical development of antibody-drug conjuga…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2981,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/antibody-drug-conjugates-for-multiple-myeloma-an-interview-with-dr-douglas-w-sborov/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/hematologic-oncology-update-916423/antibody-drug-conjugates-for-multiple-myeloma-an-interview-with-dr-douglas-w-sborov.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}